About Sensi Star
SnSIndica HybridHigh Times Cannabis Cup winner for 1999, 2000 and 2005. Highlife Cup Hydro winner in 2009 and 2010.
Bred by Paradise Seeds
Sensi Star is an award-winning indica dominant hybrid. Sensi Star was created by the crew at Paradise Seeds and they have not released the full truth of this strain's genetics. They have stated that it is mostly an Afghani indica but the strain most definitely contains some sativa, possibly Skunk, in her lineage (we estimate it at 35 percent).
The nuggets develop into dark, dark green cones that are covered with trichomes. They develop clusters of long, orange hairs. Sensi Star smells of a coniferous forest, mint, pepper, and a citrus lemon; which is similar to the taste of the strain.
Growing well in the Sea of Green technique, Sensi Star flowers for about seven weeks. Indoor this strain can yield up to 450 grams per plant, though reportedly it can produce up to three and a half pounds when grown properly. It does well when grown with a hydroponics setup. Sensi Star usually tops out at a height of six feet.
Description provided by Wikileaf.
Information provided could come from a third-party source, and likely does not accurately reflect characteristics of the medication we're associating it with - we primarily provide these descriptions for those interested in strain lineage and history, which could also be inaccurate. Any information which could be taken as medical advice should be strictly disregarded. Please consult your doctor regarding the suitability of medications for your condition(s).
About Lyphe Group Ltd
From Lyphe Group, a range of medical flowers and oils focused on giving doctors reassurance in the efficiency and consistency of our supply chain, while providing quality pharmaceutical-grade medication.
At Lyphe our vertical operations span product manufacturing, clinical care, pharmacy dispensing and doctor education. Our direct-to-patient and technology-led approach has quickly established us as the market’s largest player, with a 30% share of all patients. We have also recently entered the Australian market, where we intend to replicate our model of success.
lyphegroup.com